70 patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to 5 mg/mL TID , 2 mg/mL TID , and 5 mg/mL QD pazopanib eye drops for 28 days in a multicentre , double-masked trial with an optional safety extension for up to 5 additional months .